Why the GLP-1 weight-loss pens ran out worldwide
From 2022 to early 2025, pharmacy shelves for GLP-1 weight-loss pens often sat empty because demand grew far faster than factories could make the pens. The FDA has now declared the semaglutide and tirzepatide shortages resolved, and India has its own generic semaglutide from March 2026.
Imagine your doctor gives you a prescription. You go to the pharmacy. The shelf is empty. That happened to lakhs of people using GLP-1 pens between 2022 and 2025. Let us see why, in plain words.
What is a drug shortage?
The FDA calls it a shortage when demand for a medicine is bigger than the supply. In their words, it is 'a period of time when the demand or projected demand for the drug within the United States exceeds the supply of the drug.' In simple words, more people want the pen than the company can make. Wegovy joined the FDA shortage list in March 2022. Ozempic joined in August 2022. Tirzepatide pens (Mounjaro and Zepbound) joined in December 2022. The big reason was a huge jump in demand for weight-loss use.
Then vs now
The shortage was just pharma companies being greedy.
mostly falseMostly false — explained simply. Making these pens needs special factories that take years to build. Demand jumped far faster than any factory could scale. Novo Nordisk put 'more than 42 billion Danish kroner' into new plants in Denmark. Eli Lilly raised its Indiana site to '$9 billion,' its 'largest manufacturing investment' ever. Novo even halved starter-dose supply 'to ensure supplies for existing patients.' That is a capacity problem, not simple greed. But the ethics point is fair: a real diabetes medicine was squeezed by lifestyle demand.
What you can do if supply is patchy
The bottom line
The GLP-1 pen shortage was real and hard, especially for people with diabetes. It is now mostly resolved in the US, and India has its own generic semaglutide from March 2026. If your pharmacy is empty, talk to your doctor. Do not ride it out alone.